MAT

Stigma and Medications for Opioid Use Disorder by R.J. Barna (4/16/2026)

Stigma and Medications for Opioid Use Disorder by R.J. Barna (4/16/2026)

It takes U.S. adults, on average, a decade or more to seek behavioral health services. There are many reasons for this, including insurance barriers and lack of services, but a significant one is the stigma and discrimination related to their situation. Stigma is one of the biggest barriers to recovery, including the stigma associated with medications for opioid use disorder (MOUD). A common misconception – even amongst some peer and recovery communities – is that medications “replace one drug with another.” Some still inaccurately claim that drug use is a “moral failing” or the result of a lack of “mental fortitude” or “willpower.” These perspectives result in harmful attitudes and behaviors that negatively impact recovery and increase the deadliness of opioid addiction. Folks in recovery may avoid, reject, or move away from treatment due to shame or poor delivery. Providers may hesitate to offer MOUD, and communities may oppose treatment programs in local care facilities.

Stigma and Medication-Assisted Treatment in Corrections by Jennifer Brown (November 2022)

Stigma and Medication-Assisted Treatment in Corrections by Jennifer Brown (November 2022)

As the opioid epidemic has continued to rage on, many strides have been made in the effort to preserve life and facilitate recovery. Part of that effort has been expanded access to FDA-approved medications to treat opioid use disorder, such as buprenorphine, methadone, and naltrexone, commonly referred to as MAT: Medication-Assisted Treatment. According to SAMHSA, MAT is “the use of medications, in combination with counseling and behavioral therapies to provide a ‘whole-patient’ approach to the treatment of substance use disorders. MAT has proved to be clinically effective and to significantly reduce the need for inpatient detoxification services.” (SAMHSA, 2022)